© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
oral ERK1/2 kinase and phosphorylation inhib
Ph. 1/2 candidate for solid tumors
from SBDD from prior lead
Journal of Medicinal Chemistry
Astex Pharmaceuticals, Cambridge, UK
The Astex ERK1/2 kinase inhibitor, ASTX029, is an oral Ph. I-II candidate for patients with advanced solid tumors. The molecule was derived from fragment screening together with structure-based design. Interestingly,…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.